Virpax Pharmaceuticals jumps on supply agreement for anti-viral spray

Virpax Pharmaceuticals

26/08/2021 14:58

** Pain drug developer's  VRPX.O  shares rise 9.5% to $18.81
    ** Co enters into an agreement with Seqens to supply
material for VRPX's clinical studies as well as for long-term
commercial supply of its experimental intranasal spray, MMS019
(https://refini.tv/3DkyDJ2)
    ** MMS019 is under development for use as an anti-viral
barrier product
    ** Seqens will conduct process development and validation of
additional large-scale commercial quantities of MMS019 at its
facilities in Devens and Newburyport, Massachusetts - VRPX
    ** Including session moves, VRPX shares have more than
doubled since their IPO in February

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))